SeaBeLife is a biopharmaceutical company that develops small molecules to treat acute and serious pathologies without effective treatment. Its innovation is based on patented molecules able to stop regulated cell death. We target acute pathologies affecting vital organs such as the liver and kidneys and prioritizing orphan diseases. Where the medical need is unmet, development and market access are facilitated, enabling patients to be treated faster. Our molecules are developed to have a rapid action on disorders as severe as sudden such as acute liver and kidney failure. This development will allow us a growth relay to other pathologies such as cardiac and cerebral ischemia but also neurodegenerative and inflammatory diseases.